{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.6","upperLimit":"19.7","value":"16.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Progression-free survival was calculated as the time from randomization to disease progression as determined by the Investigator based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier.\n\nProgressive disease requires 1 of the following:\n\n* Increase of ≥ 25% from nadir in:\n\n  * Serum M-component (absolute increase ≥ 0.5 g/dl)\n  * Urine M-component (absolute increase ≥ 200 mg/24 hours)\n  * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \\> 100 mg/dl)\n  * Bone marrow plasma cell percentage (absolute % ≥ 10%)\n* Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"OG000","title":"Pomalidomide"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat included all participants enrolled.","reportingStatus":"POSTED","timeFrame":"From randomization through the follow-up phase; Maximum duration of follow-up for PFS was 90.3 weeks.","title":"Kaplan Meier Estimates for Progression Free Survival (PFS) by Investigator Based on IMWG","type":"SECONDARY","unitOfMeasure":"weeks"}